Pills masthead

News Releases

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

201020092008200720062004

May 6, 2020
Financial and Business Highlights:

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020. "I am incredibly proud of the effort and dedication of all of our...

More
Apr 29, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 third quarter on Wednesday, May 6, 2020, after the market closes. Lannett management...

More
Apr 8, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that it is set to meet with the U.S. Food and Drug Administration (FDA) on June 9, 2020 to plan next steps for the clinical advancement of its...

More
Apr 7, 2020

Lannett in the News – Philadelphia Business Journal, April 7, 2020

More
Mar 31, 2020
--Company Has Launched Five Products in Last Three Months--

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine capsule product...

More
Mar 9, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 32nd Annual ROTH Conference on March 16, 2020 at 2:30 p.m. PT at The Ritz Carlton, in Laguna Niguel,...

More
Feb 5, 2020
Financial and Business Highlights:

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 second quarter ended December 31, 2019. "For our fiscal 2020 second quarter, strong sales across multiple...

More
Jan 30, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 second quarter on Wednesday, February 5, 2020, after the market closes. Lannett...

More
Jan 13, 2020
--Company to Commence Commercial Launch Shortly, Under Brand Name NUMBRINO®--

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway,...

More
Jan 6, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The...

More
 
Price Data
NYSELCI